<DOC>
	<DOCNO>NCT02144025</DOCNO>
	<brief_summary>Ocular Graft Versus Host Disease ( OGVHD ) serious potential complication allogeneic bone marrow transplant . The usual treatment topical cyclosporine treatment initiated damage lacrimal gland already take place . The present study aim prevent OGVHD reduced-intensity allogeneic hematopoietic transplant use topical cyclosporine immediately engraftment achieve</brief_summary>
	<brief_title>Prevention Ocular Graft-Versus-Host Disease With Topical Cyclosporine Recipients Allogeneic HSCT</brief_title>
	<detailed_description>The patient start use topical cyclosporine immediately engraftment take place ( around day 14-18 cell infusion ) continue receive one year . All &gt; 18 year old patient receive allogeneic stem cell transplant perform reduced intensity condition regimen center potential candidate study . The purpose study evaluate efficacy topical cyclosporine prevention ocular versus graft disease use indicate immediately engraftment occur .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients write consent wish participate study Patients receive allogeneic stem cell hematopoietic transplant perform reduced intensity condition regimen &gt; 18 year old &lt; 18 year old Patients wish participate study Patients receive autologous stem cell hematopoietic transplant Patients history rheumatologic diseases Patients previous diagnosis dry eye s√≠ndrome Patients previous eye surgery disrupt corenal integrity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Ocular Graft-Versus-Host-Disease</keyword>
	<keyword>Topical Cyclosporine</keyword>
</DOC>